ArticleNature communications2021
Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer.
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- A Distal Super-Enhancer Regulates CD47 Expression and Promotes Macrophage-Mediated Phagocytosis of Ovarian Cancer Cells.bioRxiv : the preprint server for biology · 2026Article
- Impact of Anatomical Site on RNA-Based Molecular Subtypes in Paired High-Grade Serous Ovarian Carcinoma Samples.Cancers · 2026Article
- Recurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancer.Nature communications · 2026Article
- Neural stem cell delivery of oncolytic CRAd-S-pk7 immunotherapy for stage 3 ovarian cancer: Dose-regimen studies.Molecular therapy. Oncology · 2026Article
- Mapping CSC-Mediated Ovarian Cancer Chemoresistance via CXCR4-PET to Guide Precision Cisplatin Re-Sensitization Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Multimodal imaging reveals a lysosomal drug reservoir that drives heterogeneous distribution of PARP inhibitors.Nature communications · 2026Article
- Pareto optimality reveals an atlas of cellular archetypes.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Role of Imaging Techniques in Ovarian Cancer Diagnosis: Current Approaches and Future Directions.Cancers · 2026Review
- Single-Cell RNA-Sequencing of Peripheral Blood Reveals Neutrophil Heterogeneity in Childhood ANCA-Associated Vasculitis.Journal of inflammation research · 2026Article
- Divergent oncogenic signaling and immune microenvironment changes in low-grade serous ovarian cancer patients undergoing intraperitoneal chemotherapy.NPJ precision oncology · 2025Article
- Pan-cancer profiling links C1orf50 to DNA repair and immune modulation in ovarian cancer.Journal of ovarian research · 2025Article
- Radiomics and radiogenomics in ovarian cancer: a review with a focus on ultrasound applications.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Review
- Proximity and metabolic activity proxies in the tumor microenvironment as predictors of survival in high grade serous ovarian cancer.iScience · 2025Article
- Graph-based deep learning for integrating single-cell and bulk transcriptomic data to identify clinical cancer subtypes.Briefings in bioinformatics · 2025Article
- Chemoresistance Evolution in Ovarian Cancer Delineated by Single-Cell RNA Sequencing.International journal of molecular sciences · 2025Article
- The Curated Cancer Cell Atlas provides a comprehensive characterization of tumors at single-cell resolution.Nature cancer · 2025Article
- Article
- CytoSimplex: visualizing single-cell fates and transitions on a simplex.Bioinformatics (Oxford, England) · 2025Article
- Metabolic Objectives and Trade-Offs: Inference and Applications.Metabolites · 2025Review
- Molecular characterization of ovarian mesonephric-like adenocarcinoma: Insights from single-cell RNA sequencing and mitochondrial metabolism.Gynecologic oncology reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
The evolution of resistance in high-grade serous ovarian cancer (HGSOC) cells following chemotherapy is only partially understood. To understand the selection of factors driving heterogeneity before and through adaptation to treatment, we profile single-cell RNA-sequencing (scRNA-seq) transcriptomes of HGSOC tumors collected longitudinally during therapy. We analyze scRNA-seq data from two independent patient cohorts to reveal that HGSOC is driven by three archetypal phenotypes, defined as oncogenic states that describe the majority of the transcriptome variation. Using a multi-task learning approach to identify the biological tasks of each archetype, we identify metabolism and proliferation, cellular defense response, and DNA repair signaling as consistent cell states found across patients. Our analysis demonstrates a shift in favor of the metabolism and proliferation archetype versus cellular defense response archetype in cancer cells that received multiple lines of treatment. While archetypes are not consistently associated with specific whole-genome driver mutations, they are closely associated with subclonal populations at the single-cell level, indicating that subclones within a tumor often specialize in unique biological tasks. Our study reveals the core archetypes found in progressive HGSOC and shows consistent enrichment of subclones with the metabolism and proliferation archetype as resistance is acquired to multiple lines of therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.